Imunon (NASDAQ:IMNN) Earns Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Imunon (NASDAQ:IMNN) in a research report sent to investors on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $29.00 price objective on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Imunon in a research note on Thursday, December 19th.

Imunon Trading Up 2.7 %

Shares of NASDAQ:IMNN opened at $0.89 on Wednesday. The stock has a fifty day simple moving average of $0.89 and a two-hundred day simple moving average of $0.96. Imunon has a 12-month low of $0.51 and a 12-month high of $3.65. The stock has a market capitalization of $12.83 million, a price-to-earnings ratio of -0.47 and a beta of 2.03.

Institutional Trading of Imunon

An institutional investor recently raised its position in Imunon stock. Geode Capital Management LLC lifted its holdings in shares of Imunon, Inc. (NASDAQ:IMNN) by 10.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 139,505 shares of the company’s stock after buying an additional 13,570 shares during the period. Geode Capital Management LLC owned approximately 0.96% of Imunon worth $133,000 at the end of the most recent reporting period. Institutional investors own 4.47% of the company’s stock.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.